"HIV Protease Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Inhibitors of HIV PROTEASE, an enzyme required for production of proteins needed for viral assembly.
| Descriptor ID |
D017320
|
| MeSH Number(s) |
D27.505.519.389.745.420 D27.505.954.122.388.077.088.420
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "HIV Protease Inhibitors".
Below are MeSH descriptors whose meaning is more specific than "HIV Protease Inhibitors".
This graph shows the total number of publications written about "HIV Protease Inhibitors" by people in this website by year, and whether "HIV Protease Inhibitors" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 1 | 1 | 2 |
| 2000 | 1 | 0 | 1 |
| 2002 | 3 | 0 | 3 |
| 2003 | 2 | 0 | 2 |
| 2004 | 3 | 0 | 3 |
| 2005 | 0 | 2 | 2 |
| 2006 | 0 | 1 | 1 |
| 2007 | 1 | 1 | 2 |
| 2008 | 3 | 1 | 4 |
| 2009 | 1 | 1 | 2 |
| 2010 | 1 | 1 | 2 |
| 2011 | 1 | 0 | 1 |
| 2012 | 2 | 1 | 3 |
| 2013 | 2 | 1 | 3 |
| 2014 | 1 | 0 | 1 |
| 2015 | 1 | 1 | 2 |
| 2016 | 1 | 2 | 3 |
| 2017 | 22 | 8 | 30 |
| 2018 | 26 | 4 | 30 |
| 2019 | 9 | 3 | 12 |
| 2020 | 4 | 5 | 9 |
| 2021 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "HIV Protease Inhibitors" by people in Profiles.
-
ACE2, TMPRSS2, and L-SIGN Expression in Placentae From HIV-Positive Pregnancies Exposed to Antiretroviral Therapy-Implications for SARS-CoV-2 Placental Infection. J Infect Dis. 2021 Dec 08; 224(Supplement_6):S631-S641.
-
The comparison of favipiravir and lopinavir/ritonavir combination in COVID-19 treatment Turk J Med Sci. 2021 08 30; 51(4):1624-1630.
-
Comment on "Comparative Population Pharmacokinetics of Darunavir in SARS-CoV-2 Patients vs. HIV Patients: The Role of Interleukin-6". Clin Pharmacokinet. 2021 06; 60(6):829-831.
-
Repositioning HIV protease inhibitors and nucleos(t)ide RNA polymerase inhibitors for the treatment of SARS-CoV-2 infection and COVID-19. Eur J Clin Pharmacol. 2021 Sep; 77(9):1297-1307.
-
Outcome of a HIV Positive Patient Infected with COVID-19 After an Autologous Bone Marrow Transplantation: A Case Report. Curr HIV Res. 2021; 19(4):377-382.
-
Lopinavir/Ritonavir for COVID-19: a Systematic Review and Meta-Analysis. J Pharm Pharm Sci. 2021; 24:246-257.
-
Combination therapy of IFNß1 with lopinavir-ritonavir, increases oxygenation, survival and discharging of sever COVID-19 infected inpatients. Int Immunopharmacol. 2021 Mar; 92:107329.
-
Effect of hydroxychloroquine, azithromycin and lopinavir/ritonavir on the QT corrected interval in patients with COVID-19. J Electrocardiol. 2021 Jan-Feb; 64:30-35.
-
Analysis of the efficacy of HIV protease inhibitors against SARS-CoV-2's main protease. Virol J. 2020 11 26; 17(1):190.
-
First patient management of COVID-19 in Changsha, China: a case report. BMC Infect Dis. 2020 Nov 11; 20(1):824.